The app lication value of tumormarkers HE4 and CA125 in ovarian tumor
LI Feng1 HE Hua2 ZHU Ya-fei1 JIANG Li-xia2 WANG Qin1
1.Department of Gynecology，the First Affiliated Hospital of Gannan Medical College in Jiangxi Province，Ganzhou 341000，China；
2.Department of Clinical Laboratory，the First Affiliated Hospital of Gannan Medical College in Jiangxi Province，Ganzhou 341000，China
Abstract：Objective To establish a simple and effectivemethod of predicting ovarianmalignant tumor by the detection of serum human epididymis protein 4 （HE4）and carbohydrate antigen 125 （CA125）of patients with ovarian tumor. Methods Serum HE4 and CA125 levels of 453 patients with ovarian tumor in our hospital from January 2013 to December 2014 were determined by Roche electrochemical luminescence method.Among them，80 patients with ovarian malignant tumor，373 patientswith ovarian benign tumors（including 135 cases of ovarian endometriosis cyst，116 cases of ovarian teratoma，45 cases ofmucous and serous cystadenoma，51 cases of ovarian simple cyst and 26 cases of corpus luteum cyst）.All the results were statistically analysed.Results Comparison of serum HE4 levels between patients with ovarian benign tumor，there was no statistically significant difference （P＞0.05）；serum CA125 level of ovarian endometriosis cyst group was higher than that of other groups，the differencewas statistically significant（P＜0.05），Comparison between the rest of the group，there was no statistically significant difference （P＞0.05）.If compared with benign ovarian tumors，serum HE4 cut-off value was 126.2 pmol/L，the clinical diagnosis sensitivity in patients with ovarian malignant tumorwas 72.5%.Conclusion HE4 and CA125 are better clinical auxiliary diagnosis indicator of ovarian tumor.
李峰；何华；朱亚飞；江丽霞；王琴. HE4和CA125在卵巢肿瘤中的应用价值[J]. 中国当代医药, 2016, 23(26): 43-45.
LI Feng；HE Hua；ZHU Ya-fei；JIANG Li-xia；WANG Qin. The app lication value of tumormarkers HE4 and CA125 in ovarian tumor. 中国当代医药, 2016, 23(26): 43-45.
Rauh-Hain JA，Krivak TC，Del Carmen MG，et al.Ovarian cancer screening and early detection in the general population［J］.Rev Obstet Gynecol，2011，4（1）：15-21.
Kenemans P，Yedema CA，Bon GG，et al.CA125 in gynecological pathology a review［J］.Eur JObstet Gynecol Reprod Biol，2003，49（1-2）：115-124.
［4］
Park Y，Lee JH，Hong DJ，et al.Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases［J］.Clin Biochem，2011，44（10-11）：884-888.
Rosen DG，Wang L，Atkinson JN，et al.Potential markers that complement expression of CA125 in epithelial ovarian cancer［J］.Gynecol Oncol，2005，99（2）：267-277.
［6］
Steffensen KD，Waldstrom M，Brandslund I，et al.Prognostic impact of prechemotherapy serum levels of HER2，CA125，and HE4 in ovarian cancer patients［J］.Int JGynecol Cancer，2011，21（6）：1040-1047.
［8］
Ferrar S，Braga F，LanzoniM，et al.Serum human epididymis protein 4 vs.carbohydrate antigen 125 for ovarian cancer diagnosis：asystematic review［J］.Clin Pathol，2013，66（4）：273-281.
［9］
Zheng H，Gao Y.Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease［J］.Int JGynecol Cancer，2012，22（6）：1000-1005.
［11］
Gislefoss RE，Langseth H，Bolstad N，et al.HE4 as an early detection biomarker of epithelial ovarian cancer：investigations in prediagnostic specimens from the Janus serumbank［J］.Int JGynecol Cancer，2015，25（9）：1608-1615.
［12］
Wilailak S，Chan KK，Chen CA，et al.Distinguishing benign form malignant pelvic mass utilizing an algorithm with HE4，menopausal status，and ultrasound findings［J］.JGynecol Oncol，2015，26（1）：46-53.
京公网安备 11010502046607号